1, Shabaneh, Stevens, Stull et al. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity. J Immunother Cancer (2024) 12 (2) DOI: 10.1136/jitc-2023-008566
2, Ding, Gu, Zhong et al. A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. EBioMedicine (2020) 60, 102996 DOI: 10.1016/j.ebiom.2020.102996